BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive trends at 18 months
In addition, exploratory clinical endpoints improved compared to baseline assessments in both cohorts, with participants in the high dose cohort showing greater improvement than those in the low dose cohort.
- In addition, exploratory clinical endpoints improved compared to baseline assessments in both cohorts, with participants in the high dose cohort showing greater improvement than those in the low dose cohort.
- Time spent in the “OFF” state showed a mean decrease of 2.7 hours after 18 months.
- “We are excited to see the continued positive trends in the data from bemdaneprocel’s phase I trial at 18 months,” said Ahmed Enayetallah, Senior Vice President and Head of Development at BlueRock Therapeutics.
- “There are good reasons to be optimistic about these early data, and we are excited to move to phase II later this year.”